Compare SURG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | MAIA |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 44.9M |
| IPO Year | N/A | 2022 |
| Metric | SURG | MAIA |
|---|---|---|
| Price | $1.76 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | 133.3K | ★ 454.0K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,372,555.00 | N/A |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $122.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $0.87 |
| 52 Week High | $3.47 | $2.74 |
| Indicator | SURG | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 53.94 |
| Support Level | $1.66 | $1.07 |
| Resistance Level | $2.01 | $1.25 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 25.32 | 55.93 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.